Glembatumumab vedotin

Research use only, not for human use.

Glembatumumab vedotin (CDX-011) is an antibody-drug conjugate with potent anticancer effects, utilized in the study of triple negative breast cancer (TNBC).

Glembatumumab vedotin (CDX-011) is an ADC (antibody-drug conjugates (ADCs)) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.

Cell Viability Assay Cell Line:Osteosarcoma cell lines Concentration:1 μg/mL to 125 μg/mL Incubation Time:96 hours Result:Demonstrated osteosarcoma cytotoxic activity.

Animal Model:Athymic mice (6-week-old) injected with human SK-MEL-2 and SK-MEL-5 melanoma cells Dosage:1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg, 60 mg/kg, 80 mg/kg Administration:i.v.; every 4 days; for 16 days Result:Showed inhibition of tumor growth.

——

Others

Other Targets

Microtubule Associated | Antibody-Drug Conjugates (ADCs)

——

——

1182215-65-1

Approximatel 149.16 kDa

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years